DK3022192T3 - Piperidinylindole derivatives and their use as complement factor B inhibitors - Google Patents

Piperidinylindole derivatives and their use as complement factor B inhibitors Download PDF

Info

Publication number
DK3022192T3
DK3022192T3 DK14744744.5T DK14744744T DK3022192T3 DK 3022192 T3 DK3022192 T3 DK 3022192T3 DK 14744744 T DK14744744 T DK 14744744T DK 3022192 T3 DK3022192 T3 DK 3022192T3
Authority
DK
Denmark
Prior art keywords
methyl
indol
methoxy
piperidin
dimethyl
Prior art date
Application number
DK14744744.5T
Other languages
Danish (da)
English (en)
Inventor
Christopher Adams
Michael Paul Capparelli
Takeru Ehara
Rajeshri Ganesh Karki
Chun Zhang
Nello Mainolfi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51230246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3022192(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3022192T3 publication Critical patent/DK3022192T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK14744744.5T 2013-07-15 2014-07-14 Piperidinylindole derivatives and their use as complement factor B inhibitors DK3022192T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361846355P 2013-07-15 2013-07-15
US201461977028P 2014-04-08 2014-04-08
PCT/US2014/046515 WO2015009616A1 (en) 2013-07-15 2014-07-14 Piperidinyl indole derivatives and their use as complement factor b inhibitors

Publications (1)

Publication Number Publication Date
DK3022192T3 true DK3022192T3 (en) 2018-01-22

Family

ID=51230246

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14744744.5T DK3022192T3 (en) 2013-07-15 2014-07-14 Piperidinylindole derivatives and their use as complement factor B inhibitors

Country Status (40)

Country Link
US (2) US9682968B2 (enExample)
EP (2) EP3299365A1 (enExample)
JP (1) JP6378761B2 (enExample)
KR (1) KR102242742B1 (enExample)
CN (1) CN105579444B (enExample)
AP (1) AP2016008992A0 (enExample)
AU (1) AU2014290298B2 (enExample)
BR (1) BR112016000909B1 (enExample)
CA (1) CA2917839C (enExample)
CL (1) CL2016000060A1 (enExample)
CU (1) CU24397B1 (enExample)
CY (2) CY1119767T1 (enExample)
DK (1) DK3022192T3 (enExample)
EA (1) EA031030B1 (enExample)
ES (1) ES2655855T4 (enExample)
FI (1) FIC20240032I1 (enExample)
FR (1) FR24C1036I2 (enExample)
GT (1) GT201600007A (enExample)
HR (1) HRP20172000T1 (enExample)
HU (2) HUE037510T2 (enExample)
IL (2) IL243540B (enExample)
JO (1) JO3425B1 (enExample)
LT (2) LT3022192T (enExample)
MX (1) MX351291B (enExample)
MY (2) MY196427A (enExample)
NL (1) NL301292I2 (enExample)
NO (1) NO2024042I1 (enExample)
PE (1) PE20161066A1 (enExample)
PH (1) PH12016500072B1 (enExample)
PL (1) PL3022192T3 (enExample)
PT (1) PT3022192T (enExample)
RS (1) RS56721B1 (enExample)
SG (1) SG11201600086PA (enExample)
SI (1) SI3022192T1 (enExample)
SV (1) SV2016005137A (enExample)
TN (1) TN2016000017A1 (enExample)
TW (1) TWI641600B (enExample)
UA (1) UA117371C2 (enExample)
UY (1) UY35663A (enExample)
WO (1) WO2015009616A1 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
CA3027500A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
EP3808748A1 (en) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
EP3448389B1 (en) * 2016-06-27 2021-09-29 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CN113444094B (zh) * 2016-07-20 2023-12-22 纳莹(上海)生物科技有限公司 一种荧光探针及其制备方法和用途
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
CN118903386A (zh) 2017-08-24 2024-11-08 诺和诺德股份有限公司 Glp-1组合物及其用途
CN117338782A (zh) 2017-08-31 2024-01-05 诺华股份有限公司 哌啶基-吲哚衍生物的用途
US11208398B2 (en) 2018-07-16 2021-12-28 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives
JP7538113B2 (ja) 2018-08-20 2024-08-21 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
CA3114039A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
US20220117949A1 (en) 2019-01-11 2022-04-21 Novartis Ag Lta4h inhibitors for the treatment of hidradenitis suppurativa
JP2021506953A (ja) 2019-01-11 2021-02-22 ノバルティス アーゲー 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体
KR20220143036A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
EP4153580A1 (en) 2020-05-18 2023-03-29 Novartis AG Crystalline form of lnp023
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors
JP7293513B2 (ja) 2020-07-16 2023-06-19 ノバルティス アーゲー Ｂ因子阻害剤の使用方法
EP4282486A3 (en) * 2020-08-07 2024-03-06 Shanghai Meiyue Biotech Development Co., Ltd. Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof
US20230331710A1 (en) * 2020-08-07 2023-10-19 Shanghai Meiyue Biotech Development Co. Ltd Heterocyclic compound, preparation method and use thereof
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物
US20250250267A1 (en) * 2020-12-30 2025-08-07 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing bridged heterocyclic compound, preparation method therefor, and medical use thereof
CA3203447A1 (en) * 2020-12-30 2022-07-07 Kevin X Chen Series of piperidine-substituted benzoic acid compounds, and use thereof
US20240182503A1 (en) * 2021-01-14 2024-06-06 Alexion Pharmaceuticals, Inc. Macrocycle complement factor b inhibitors
US20240217953A1 (en) * 2021-04-16 2024-07-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic substituted aromatic carboxylic acid compounds
US20240238266A1 (en) * 2021-05-07 2024-07-18 Novartis Ag Iptacopan for the treatment of atypical hemolytic uremic syndrome
KR20240017004A (ko) * 2021-06-03 2024-02-06 치누크 세라퓨틱스, 인크. 치환된 인돌 화합물 및 이의 사용 방법
CN117500500A (zh) 2021-06-18 2024-02-02 诺华股份有限公司 治疗自身免疫性血液病的方法
US20240360103A1 (en) * 2021-06-30 2024-10-31 Apellis Pharmaceuticals, Inc. Complement inhibition
CA3229360A1 (en) * 2021-08-18 2023-02-23 Chen Zhang Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
JP2024530344A (ja) 2021-09-07 2024-08-16 ノバルティス アーゲー 加齢黄斑変性の処置のためのｂ因子阻害剤の使用
AU2022376760A1 (en) * 2021-10-27 2024-05-02 Hansoh Bio Llc Piperidinyl indole derivatives, preparation methods and medicinal uses thereof
EP4469157A1 (en) 2022-01-24 2024-12-04 Novartis AG Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
AU2023210941A1 (en) * 2022-01-26 2024-07-11 Shanghai Meiyue Biotech Development Co., Ltd. Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
JP2025507830A (ja) 2022-03-04 2025-03-21 ノバルティス アーゲー ループス腎炎の処置のためのイプタコパンの使用
JP2025511100A (ja) 2022-04-01 2025-04-15 ノバルティス アーゲー 補体因子ｂ阻害剤及びその使用
WO2023246677A1 (zh) * 2022-06-20 2023-12-28 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
WO2023246870A1 (zh) * 2022-06-23 2023-12-28 上海济煜医药科技有限公司 吲哚化合物的制备、应用及用途
EP4549435A4 (en) * 2022-06-30 2025-11-12 Jiangsu Hengrui Pharmaceuticals Co Ltd Pharmaceutically acceptable salt and crystalline form of nitrogen-bridged heterocyclic derivative and their preparation process
WO2024046277A1 (zh) * 2022-08-29 2024-03-07 南京明德新药研发有限公司 一系列含氮桥杂环化合物及其制备方法
TW202423426A (zh) * 2022-08-31 2024-06-16 美商奇努克醫療股份有限公司 經取代之吲哚化合物及其使用方法
WO2024051849A1 (en) 2022-09-10 2024-03-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. 2-substituted piperidine derivatives, preparation methods and medicinal uses thereof
KR20250103768A (ko) 2022-11-11 2025-07-07 상하이 이셩 바이오파마슈티컬 컴퍼니 리미티드 피리딘 치환 벤조산계 화합물, 이의 약학 조성물 및 용도
TW202434558A (zh) * 2022-11-14 2024-09-01 美商奇努克醫療股份有限公司 補體因子ｂ抑制劑之固體形式
WO2024114677A1 (zh) * 2022-11-29 2024-06-06 上海济煜医药科技有限公司 苯并螺环吲哚化合物的制备、应用及用途
CN120435467A (zh) * 2022-12-31 2025-08-05 珠海联邦制药股份有限公司 补体因子b抑制剂及其药物组合物和应用
WO2024148274A1 (en) * 2023-01-05 2024-07-11 Apellis Pharmaceuticals, Inc. Complement inhibition
AU2024226460A1 (en) * 2023-02-22 2025-09-11 Haisco Pharmaceutical Group Co., Ltd. Pharmaceutical composition of benzo nitrogen heteroaromatic ring derivative and use thereof in medicine
IL322259A (en) 2023-02-23 2025-09-01 Novartis Ag Methods of using factor b inhibitors
TW202438499A (zh) * 2023-03-21 2024-10-01 大陸商上海美悦生物科技發展有限公司 螺環類化合物及其藥物組合物、製備方法和用途
WO2025008451A1 (en) 2023-07-04 2025-01-09 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors
WO2025008453A1 (en) 2023-07-04 2025-01-09 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)-isoindoline derivatives as factor b inhibitors
WO2025008516A2 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Novel compounds
WO2025008517A1 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Indole derivatives with factor b inhibitory activity
CN119371402A (zh) * 2023-07-26 2025-01-28 上海美悦生物科技发展有限公司 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途
TW202508580A (zh) 2023-08-25 2025-03-01 瑞士商諾華公司 使用因子b抑制劑之方法
WO2025068951A1 (en) 2023-09-29 2025-04-03 Novartis Ag Complement factor b inhibitors and uses thereof
WO2025083621A1 (en) 2023-10-20 2025-04-24 Novartis Ag Treatment of hidradenitis suppurativa using anti-baff-r antibodies
TW202535375A (zh) * 2023-12-05 2025-09-16 大陸商西藏海思科製藥有限公司 苯並氮雜芳環衍生物在治療補體因數b介導的疾病中的用途
WO2025148628A1 (zh) * 2024-01-10 2025-07-17 河北以岭医药研究院有限公司 哌啶基吲哚衍生物及其制备方法和应用
WO2025172535A1 (en) 2024-02-15 2025-08-21 Sitala Bio Ltd Indole and benzimidazole compounds as factor b inhibitors
WO2025172910A1 (en) 2024-02-16 2025-08-21 Novartis Ag Factor b inhibitors for treatment of anca-associated vasculitis
WO2025185734A1 (zh) * 2024-03-08 2025-09-12 江苏豪森药业集团有限公司 一种多元螺环化合物的盐及其晶型、其制备方法和医药用途
WO2025237237A1 (en) * 2024-05-11 2025-11-20 Alebund Pharmaceuticals (Hong Kong) Limited Complement factor b inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030357A1 (es) 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10237723A1 (de) 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
DK1585743T3 (da) 2002-12-19 2007-09-17 Pfizer 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EA200501713A1 (ru) 2003-04-30 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Фенилзамещённые карбоновые кислоты
EP1836182A2 (en) 2004-11-18 2007-09-26 The Institutes for Pharmaceutical Discovery, LLC Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
AU2006212951A1 (en) * 2005-02-08 2006-08-17 Merck & Co., Inc. Inhibitors of checkpoint kinases
WO2009042092A1 (en) 2007-09-25 2009-04-02 Merck & Co., Inc. 2-aryl or heteroaryl indole derivatives
US20100331298A1 (en) 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
ES2759751T3 (es) 2009-07-14 2020-05-12 Nerviano Medical Sciences Srl 3-oxo-2,3-dihidro-1H-isoindol-4-carboxamidas
CN102883607B (zh) 2010-03-01 2015-07-22 Gtx公司 用于治疗癌的化合物
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
PE20140471A1 (es) * 2011-01-04 2014-04-13 Novartis Ag Moduladores de la via del complemento y usos de los mismos
ES2630079T3 (es) * 2012-05-04 2017-08-17 Novartis Ag Moduladores de la ruta del complemento y usos de los mismos
EP2864322B1 (en) * 2012-06-20 2016-04-27 Novartis AG Complement pathway modulators and uses thereof
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b

Also Published As

Publication number Publication date
HRP20172000T1 (hr) 2018-02-09
JP2016526576A (ja) 2016-09-05
US9682968B2 (en) 2017-06-20
CN105579444B (zh) 2018-05-01
IL243540A0 (en) 2016-02-29
AU2014290298A1 (en) 2016-02-11
JO3425B1 (ar) 2019-10-20
HK1221217A1 (en) 2017-05-26
CY1119767T1 (el) 2018-06-27
JP6378761B2 (ja) 2018-08-22
MX351291B (es) 2017-10-09
SI3022192T1 (en) 2018-01-31
TWI641600B (zh) 2018-11-21
GT201600007A (es) 2018-12-18
LT3022192T (lt) 2017-12-27
PL3022192T3 (pl) 2018-03-30
PE20161066A1 (es) 2016-10-30
WO2015009616A1 (en) 2015-01-22
CA2917839A1 (en) 2015-01-22
CN105579444A (zh) 2016-05-11
CY2024027I2 (el) 2025-09-26
BR112016000909A2 (pt) 2017-07-25
MY196427A (en) 2023-04-10
US20180009795A1 (en) 2018-01-11
HUS2400034I1 (hu) 2024-10-28
EP3299365A1 (en) 2018-03-28
AP2016008992A0 (en) 2016-01-31
US20160152605A1 (en) 2016-06-02
IL268623A (en) 2019-10-31
KR20160030556A (ko) 2016-03-18
EA031030B1 (ru) 2018-11-30
CU20160006A7 (es) 2016-08-31
FR24C1036I2 (fr) 2025-08-01
KR102242742B1 (ko) 2021-04-23
RS56721B1 (sr) 2018-03-30
TW201546058A (zh) 2015-12-16
BR112016000909B1 (pt) 2023-05-02
CL2016000060A1 (es) 2016-06-10
NZ715780A (en) 2021-03-26
TN2016000017A1 (en) 2017-07-05
SG11201600086PA (en) 2016-02-26
AU2014290298B2 (en) 2017-06-15
NO2024042I1 (no) 2024-09-30
IL243540B (en) 2019-09-26
NL301292I2 (nl) 2024-10-30
LTPA2024526I1 (enExample) 2024-10-10
ES2655855T4 (es) 2024-09-06
PH12016500072A1 (en) 2016-04-18
UY35663A (es) 2015-02-27
SV2016005137A (es) 2018-06-12
EA201690223A1 (ru) 2016-06-30
US10093663B2 (en) 2018-10-09
EP3022192B1 (en) 2017-10-11
EP3022192A1 (en) 2016-05-25
BR112016000909A8 (pt) 2020-01-07
IL268623B (en) 2020-01-30
FIC20240032I1 (fi) 2024-10-01
CU24397B1 (es) 2019-04-04
PT3022192T (pt) 2018-01-15
MY187454A (en) 2021-09-22
CA2917839C (en) 2022-05-03
UA117371C2 (uk) 2018-07-25
FR24C1036I1 (fr) 2024-12-06
HUE037510T2 (hu) 2018-09-28
PH12016500072B1 (en) 2016-04-18
ES2655855T3 (es) 2018-02-21
CY2024027I1 (el) 2025-09-26

Similar Documents

Publication Publication Date Title
DK3022192T3 (en) Piperidinylindole derivatives and their use as complement factor B inhibitors
US9550755B2 (en) Complement pathway modulators and uses thereof
US9475806B2 (en) Complement factor B inhibitors and uses there of
US9388199B2 (en) Pyrrolidine derivatives and their use as complement pathway modulators
US9676728B2 (en) 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
US20150191462A1 (en) Pyrrolidine derivatives and their use as complement pathway modulators
US20150322060A1 (en) Pyrrolidine derivatives and their use as complement pathway modulators
HK1221217B (en) Piperidinyl indole derivatives and their use as complement factor b inhibitors
NZ715780B2 (en) Piperidinyl indole derivatives and their use as complement factor b inhibitors
NZ754317B2 (en) Piperidinyl indole derivatives and their use as complement Factor B inhibitors
NZ754317A (en) Piperidinyl indole derivatives and their use as complement Factor B inhibitors